Announcements.
Looking to discover a little more about our client companies?
A selection of news and recent announcements can be found here.
Northcoders Group PLC – New Consultancy contract wins
RNS Number : 9938C Northcoders Group PLC 01 April 2025 This is a Reach (i.e. non-regulatory) announcement, and the information contained is not considered to be material or to have a significant impact on management's expectations of the Company's performance 1April2025 Northcoders Group PLC ('Northcoders', the……
RNS Number : 9938C
Northcoders Group PLC
01 April 2025
This is a Reach (i.e. non-regulatory) announcement, and the information contained is not considered to be material or to have a significant impact on management's expectations of the Company's performance
|
|
1April2025 |
Northcoders Group PLC
('Northcoders', the 'Group' or the 'Company')
New Consultancy contract wins
Northcoders to provide digital training to leading UK Building Society
and Manchester Airports Group
Northcoders (AIM:CODE), a market leader in technology training in the UK, is pleased to announce that its consultancy brand, Counter® has secured new contracts with Skipton Building Society ('Skipton'), one of the leading UK-based mutual financial services groups, and Manchester Airports Group ('MAG').
Following the successful integration of a Data Engineering team in 2024, Skipton has agreed terms for a second consultancy contract with Counter® in line with its strategy to grow internal capabilities and deliver its ambitious technology strategy. This team is supporting the delivery of the Society's brand-new customer web and mobile applications for its members using the Northcoders business model of deploying advanced engineers from Northcoders alumni and the Group's Tech Returners business. Beyond the immediate delivery to Skipton's members, a key benefit to the Society is the option for the Consultants to join Skipton for the next stage of their career.
Following an initial six-month engagement with MAG, a further three-month contract extension has been agreed. The embedded team of technologists will be working on a project to enhance MAG's three airport websites, and delivering an improved mobile experience.
Chris Hill, CEO of Northcoders, said:"We are delighted to announce the new contracts for our consultancy division, reflecting the recent progress made by Counter® in disrupting the traditional, hire, train, deploy market. With a focus specifically on the underserved technology training market, and offering the best-in-class Consultants, we are beginning to build a brand, relationships and pipeline to take material market share in the medium term, particularly with return customers like Manchester Airports Group.
"This demonstrates the successful diversification of Northcoders revenues as we mature as a business, addressing the UK's significant digital skills gap in private and public services and meeting technology transformation aspirations over the coming years."
June Powell, Engineering Enablement Lead, Skipton Building Society, said:"I had the pleasure of working with Counter® last year on a project, and I am delighted to have the opportunity to collaborate with them again in a different area of our business. I look forward to seeing more of their skills and experience in action as they continue to support The Society in our ongoing evolution. Their collaborative approach and the time they dedicate to truly understanding our culture make them an ideal fit for Skipton."
– Ends –
|
For further enquiries:
|
|
|
||||||||||||||||||||||||
Notes to Editors
Northcoders is a market leading provider of technology training for businesses and individuals with courses in, Software Engineering, Data Engineering, AI and Machine Learning, and Platform Engineering. Founded in 2015, the Group provides the highest quality online training to students across the UK via its proven NCore technology platform.
Powered by IP rich technology, Northcoders offers boot camp courses to individuals from a range of backgrounds, delivered through virtual and physical learning. The Group also works with blue chip corporates across multiple sectors to help them to achieve their digital requirements, with teams as a service and to supply innovative solutions for the upskilling and reskilling of employees. With a keen focus of inclusivity, diversity and quality at its core, Northcoders aims to address the digital skills gap in the UK to meet the increasing demand for digital specialists at all levels, from businesses and public agencies.
Northcoders was admitted to trading on AIM in July 2021 with the ticker CODE.L. For additional information please visitinvestors.northcodersgroup.com.
About Counter®
Counter®specialises in deploying UK-based teams of technologists into corporate clients, building dedicated teams that align technically and culturally with clients' long-term goals. Counter®is a challenger brand to the current tech consultancy, Offshore and Hire, Train and Deploy sector by offering a different approach underpinned by an efficient and scalable business model based on 100% utilisation rates for its Counter®consultants.
Counter®'s Consultants have either completed Northcoders' training and are proficient in modern cloud and software solutions, including AI/ML development, data and cloud engineering or are part of the Tech Returners network. The consultancy's robust model ensures that at the end of each engagement, clients have the option to onboard the consultants as full-time employees ('FTEs'), at no additional cost, reinforcing skill retention and continuity.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRABUGDXCSXDGUB
CloseCroma Security Solutions Group PLC – Acquisition
RNS Number : 9559C Croma Security Solutions Group PLC 01 April 2025 01 April 2025 Croma Security Solutions Group Plc ("CSSG", "Croma", "the "Company" or the "Group") Acquisition of Peterborough Locksmith Croma Security Solutions Group plc (AIM:CSSG) is pleased to announce that it has completed the acquisition of……
RNS Number : 9559C
Croma Security Solutions Group PLC
01 April 2025
01 April 2025
Croma Security Solutions Group Plc
("CSSG", "Croma", "the "Company" or the "Group")
Acquisition of Peterborough Locksmith
Croma Security Solutions Group plc (AIM:CSSG) is pleased to announce that it has completed the acquisition of Benn Lock and Safe Limited ("Benn Lock & Safe"), a well-established, Peterborough based locksmith and security provider for a total consideration of £200,000, to be satisfied as to £166,667 in cash and the balance through the issue of 38,535 ordinary shares which will be issued from Treasury at an issue price of 86.50 pence per share ("Consideration Shares"), representing average of the closing middle quotations over the five dealing days ending on the dealing day immediately before the completion Date.
Benn Lock & Safe was founded nearly 50 years ago, originally operating as a pure locksmith service before expanding into fire and electronic security solutions. The business has developed specialist expertise in servicing schools and multi-occupancy properties and is trusted by local vendors, police forces, and government sectors across Cambridgeshire. Benn Lock & Safe has developed its reputation through both a physical storefront in Peterborough and a successful online presence.
Croma already has a locksmith store in Peterborough, operating less than two miles from Benn Lock & Safe. The acquisition will enable Benn Lock & Safe to be combined with Croma's Peterborough branch, consolidating the two businesses into a single security centre. This will naturally create immediate cost savings and synergies but equally importantly, it will become the sole centre for security and locksmith services in the Peterborough area. The lease on the Benn Lock & Safe retail property allows for a 12-month break clause.
For the 12 months to 31 March 2024 Benn Lock & Safe generated revenues of £675,000 and profit before tax of £40,000. As at 28 February 2025, the net asset value of the assets being acquired was £90,000.
Phil Hunt, Managing Director of Benn Lock & Safe, said: "We have always prided ourselves on delivering expert locksmith and security services to our customers, and I am looking forward to continuing to do so as part of Croma. The Group's well-established model will provide us with the operational support and resources to enhance our offering while maintaining the trusted service that Benn Lock & Safe is known for."
Roberto Fiorentino, Chief Executive Officer, commented:"We are very pleased to welcome Benn Lock & Safe into the Group. This is a strategic acquisition for us, and also one that further evidences our acquisition model gaining traction, with independent locksmiths recognising the benefits of being part of our network. Benn Lock & Safe has seen first-hand how another locksmith in the area has successfully integrated into our proven model, which gave them confidence in making this transition. We believe this trend will continue, as we progress our pipeline of acquisition opportunities."
Total Voting Rights
Following the issue of the Consideration Shares from Treasury, the Company will continue to have 15,898,656 Ordinary Shares in issue, but with 2,130,401 held in treasury. Accordingly, the total number of voting rights in the Company will be 13,768,255 and shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information visit www.cssgroupplc.com or contact:
Croma Security Solutions Group Plc Tel: +44 44 (0)1489 566 166
Roberto Fiorentino, CEO
Teo Andreeva, CFO
Zeus Tel: +44 (0)207 220 1666
(Nominated Adviser and Broker)
Mike Coe
James Bavister
Novella Tel: +44 (0)203 151 7008
Tim Robertson
Chris Marsh
Safia Colebrook
Notes to editors:
Croma Security Solutions is an expanding technology led security solutions provider with over 50 years of specialist experience, delivering high-quality security solutions across locksmith, fire and security services for both domestic and commercial environments. The Groups network currently stands at 17 security centres, stretching from its headquarters in Southampton, across the Midlands and up to the Northwest. Croma services a range of sectors including health, education, leisure and entertainment, and utilities, and is trusted by national brands, including multiple NHS Trusts, with their complex security needs.
Croma's growth strategy is focused on establishing a national security network. In 2023, it sold its man-guarding business Vigilant for £6.5m, which has provided the capital to fund the expansion of the business. Croma is a proven acquirer of local, traditional locksmith businesses, which are developed into its network of modern security centres, offering both total security solutions and locksmith services to retail and commercial customers. The new security centres benefit from extended product ranges, centralised group services, and both a local and national customer base. Since the sale in 2023, Croma has added new businesses to its network, and has a strong pipeline of further locksmiths stores to be acquired into the network.
Croma is listed on the AIM market of the London Stock Exchange. Founded in 1970, it is headquartered in Southampton and has over 90 employees.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
ACQJBMBTMTJJBLA
CloseTracsis PLC – Contract signed for Tap Converter system
RNS Number : 5971X Tracsis PLC 19 February 2025 19 February 2025 Tracsis plc ("Tracsis" or "the Group") Contract signed for pay-as-you-go Tap Converter system Tracsis (LSE: TRCS), a leading transport technology provider, is pleased to announce that, further to the announcement of Preferred Bidder status……
RNS Number : 5971X
Tracsis PLC
19 February 2025
19 February 2025
Tracsis plc
("Tracsis" or "the Group")
Contract signed for pay-as-you-go Tap Converter system
Tracsis (LSE: TRCS), a leading transport technology provider, is pleased to announce that, further to the announcement of Preferred Bidder status on 26 November 2024, it has signed a multi-year contract withRail Settlement Plan, a division of Rail Delivery Group (RDG), to implement the core Tap Converter system that will powerpay-as-you-go (PAYG) travel in urban areas across National Rail, processing all related transactions and fare calculations.
Highlights
· Major contract win, through a competitive bid process, to provide the central smart ticketing technology platform enabling PAYG travel in urban areas across National Rail.
· The nationwide rollout of PAYG is central to the UK Government's stated vision for modernising rail travel with ticketing simplification and innovation high on its agenda.
· Six Train Operating Companies (TOCs) on theNational Rail network currently use Tracsis' smart ticketing technology. This contract provides a long-term revenue opportunity as TOC and consumer adoption grows.
· All Tracsis development activities are fully funded. Once deployed, the contract delivers a guaranteed minimum annual operating fee with additional transaction revenues based on the volume of PAYG transactions processed.
· Development starts immediately with deployment and transactional revenue generation expected to begin in 2026.
Background
The Tap Converter system will be a centralised smart ticketing technology platform that processes 'tap' data from various sources such as smartcards, contactless bankcards and mobile apps/barcodes when passengers tap in and out at stations. It will also integrate with multiple modes of transport, supporting the delivery of London style PAYG ticketing for rail, bus and tram travel.
Tracsis will utilise its existing technology to construct journeys from these taps calculating the best fare while automatically applying entitlements, concessions, discounts and fare caps. Once calculated, the system provides this fare information to the TOC to charge the passenger and submits settlement records to the rail industry's settlement engine.
Tracsis is currently the only provider of an accredited PAYG ticketing platform on the National Rail network outside London, and this contract significantly extends the potential reachof Tracsis' technology. With the government and industry-wide push towards smarter, more flexible digital ticketing, PAYG adoption is expected to expand across the network, though the pace will vary by operator and region.
Timeline, Opportunity and Revenue Model
Tracsis has begun a period of funded development with deployment expected to begin in 2026. The six TOCs currently offering a PAYG solution using Tracsis' technology will continue to do so during this period.
Once the Tap Converter system is operational, Tracsis revenues will be based on the volume of transactions processed and this willbe driven by future customer adoption rates and system usage.
A total of 1.7 billion rail passenger journeys were recorded across Great Britain in the 12 months to September 20241.Tracsis estimates that PAYG transaction volumes using the Tap Converter system could in the medium term equate to 10-15% of total annual passenger journeys with commuters expected to drive the highest adoption rates.
In 2024, Tracsis processed 2.25 million PAYG journeys. With the recent go-live of new PAYG deployments in Wales (contactless EMV) and Scotland (Tap&Pay) we expect to see accelerated growth in passenger journeys over the coming months ahead of the deployment of the Tap Converter system.
Transaction revenues from the Tap Converter system will start to accrue following deployment which is forecast to start in 2026. There is no change to the Board's expectation for the year ending 31 July 2025 following this contract win and Tracsis will issue its trading update on H1 performance on 26 February 2025.
Chris Barnes, Chief Executive Officer of Tracsis, commented:
"Weare delighted to be working with the Rail Delivery Group and Great British Railways Transition Team (GBRTT) to deliver this important pay-as-you-go ticketing solution on a nationwide basis. The contract represents a major milestone in our smart ticketing technology journey, with the potential to grow into a valuable, long-term partnership over time.
Digital transformation remains integral to the rail industry's future. The Government has made a commitment to expand pay-as-you-go ticketing across urban areas on the National Rail network and the Tap Converter system will position Tracsis as an important technology provider at the heart of this transformation."
Stewart Fox-Mills, Fares, Ticketing and Retail Programme Director at GBRTT and RDG, commented:
"We are working with industry partners to simplify the railway fares and ticketing system, making travel more convenient and flexible for all passengers. We are committed to developing a simpler fare system that enhances the overall customer experience and supports the long-term growth of rail travel.
The delivery of pay-as-you-go ticketing in urban areas is a high priority and we look forward to working with Tracsis on delivering the Tap Converter system that will provide the technical foundation for pay-as-you-go ticketing in urban areas."
1Source: Office of Rail and Road passenger rail usage data (published 19 December 2024)Passenger rail usage | ORR Data Portal
Enquiries:
|
Tracsis plc Chris Barnes, CEO Andy Kelly, CFO
|
+44 (0)845 125 9162 |
|
Berenberg (Nominated Adviser, Corporate Broker & Financial Adviser) Mark Whitmore / Richard Andrews / Mollie D'Arcy Rice James Thompson (QE)
|
+44 (0)20 3207 7800 |
|
Alma Strategic Communications |
+44 (0)20 3405 0205 tracsis@almastrategic.com |
Notes to editors:
· Tracsis plc is a technology company and a leading provider of software and hardware products, data capture and data analytics/GIS services for the rail, traffic data and wider transport industries.
· Tracsis's products and services are widely used to increase efficiency, reduce cost and risk, improve operational and asset performance, improve safety management and decision making capabilities and improve the overall end-user experience for clients and customers.
· The Group is split into two principal operating areas built around detailed industry knowledge and expertise:
– Rail Technology & Services: A software, technology and product led business. It develops and supplies software that solves complex resource, asset optimisation and control problems for Train Operators, and smart ticketing, delay repay and other retail software to improve the customer experience for rail users. It also develops remote condition monitoring hardware, data acquisition software, and safety and risk management software for rail infrastructure providers.
– Data, Analytics, Consultancy & Events: A largely services led business that focuses on data capture, data analytics, GIS, earth observation, data insights, consultancy and event traffic management within a range of transport and pedestrian rich environments. The business provides technology and bespoke products and data that underpin large scale intelligent transport systems, smart city planning and positive environmental decision making.
· Tracsis has a blue-chip client base which includes all major UK transport owning groups, Network Rail, Passenger and Freight Train Operating Companies, the Department for Transport, TfL, multiple local authorities, major outdoor music and sporting event organisers, and a wide variety of large engineering and infrastructure companies. In North America our clients include Class 1 rail freight companies, transit operators, shortline railroads and several large rail served ports and industrials.
· The business drives growth both organically and through acquisition and has made seventeen acquisitions since 2008.
For more information on Tracsis please visit http://www.tracsis.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
CNTUWURRVVUUAUR
Close2025 Party in The Paddock
RNS Number : 5703W Newbury Racecourse PLC 11 February 2025 RNS Reach – non-regulatory announcement 11 February 2025 NEWBURY RACECOURSE PLC (the "Company") 2025 Party in The Paddock The Company today announces the final act to complete its 2025 Party in the Paddock line-up. In……
RNS Number : 5703W
Newbury Racecourse PLC
11 February 2025
RNS Reach – non-regulatory announcement
11 February 2025
NEWBURY RACECOURSE PLC
(the "Company")
2025 Party in The Paddock
The Company today announces the final act to complete its 2025 Party in the Paddock line-up. In the past, the Company has hosted established acts such as Tom Jones, Meat Loaf, Olly Murs and Simply Red who have performed after racing at two key summer Saturday fixtures.
For 2025 the Company will be expanding these events and hosting a total of four events, the first of which is a double-headline combination of Sophie Ellis-Bextor and Ella Henderson on Saturday 19th July. Following this, Bjorn Again will perform on Friday 15th August and Clean Bandit on Saturday 16th August. James Bay will complete this year's line-up with a performance after racing on Saturday 20th September.
Tickets are available to purchase fromwww.newburyracecourse.co.ukwith discounts offered for early and multi-day commitment.
Shaun Hinds, Chief Executive of Newbury Racecourse, commented: "We are delighted to announce an expanded Party in the Paddock line-up for 2025. By hosting this strong line up of established and popular artists we are hopeful that we have catered for a broad variety of music tastes and look forward to a fantastic summer of music and racing at Newbury".
For further information please contact:
Newbury Racecourse plc Tel: 01635 40015
Shaun Hinds, Chief Executive
Mark Leigh, Finance Director
Allenby Capital Limited (AQSE Corporate adviser) Tel: 0203 328 5656
Nick Naylor / Liz Kirchner (Corporate Finance)
Hudson Sandler Tel: 0207 796 4133
Charlie Jack
About Reach announcements
This is a RNS Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRASFAFISEISEFE
CloseSmarttech247 Secures Three-Year Contract
RNS Number : 5923W Smarttech247 Group PLC 11 February 2025 Reach Announcement 11 February 2025 Smarttech247 Group PLC ("Smarttech247", the "Group" or the "Company") Smarttech247 Secures Three-Year Contract Worth USD 925,000 Smarttech247 (AIM: S247), a multi-award-winning provider of AI-enhanced cybersecurity services providing automated managed detection and……
RNS Number : 5923W
Smarttech247 Group PLC
11 February 2025
Reach Announcement
11 February 2025
Smarttech247 Group PLC
("Smarttech247", the "Group" or the "Company")
Smarttech247 Secures Three-Year Contract Worth USD 925,000
Smarttech247 (AIM: S247), a multi-award-winning provider of AI-enhanced cybersecurity services providing automated managed detection and response for a portfolio of international clients, is pleased to announce it has signed a new additional contract with an existing automotive client worth USD 925,000 over three years.
This new additional contract will see an Endpoint Detection & Response (EDR) solution integrated into the existing Managed Detection and Response (MDR) service already supplied to Smarttech247's automotive client. This new EDR solution is designed to detect, investigate and respond to threats on endpoint devices such as computers, laptops, and servers, enhancing the client's existing cybersecurity resilience.
This new contract also reflects the execution of the Company's strategy to expand its annual recurring revenue by focusing on long-term, multi-year contracts and increasing the total contract value of existing agreements.
Raluca Saceanu, CEO of Smarttech247, commented:
"We are thrilled to be expanding our provision of services with another existing client, reinforcing our strong, ongoing relationship and highlighting the continued trust our clients have in our MDR expertise to protect their critical infrastructure.
"As organisations worldwide increasingly prioritise advanced threat detection and response, this latest contract showcases our ability to deliver security solutions at scale as our momentum continues to build."
-Ends –
*Smarttech247 is a recognised vendor in 2024 Gartner® Market Guide for Managed Detection and Response.
For further information please contact:
|
Smarttech247 Group PLC
|
Tel: +353 21 206 6033 |
|
Ronan Murphy, Executive Chairman
Raluca Saceanu, Chief Executive Officer
Nicholas Lee, Finance Director
|
|
|
SPARK Advisory Partners Limited – Nominated Adviser
|
Tel: + 44 (0) 20 3368 3550 |
|
Mark Brady / Angus Campbell
|
|
|
Cavendish Capital Markets Limited – Corporate Broker
|
Tel: +44 (0) 20 7220 0500 |
|
Marc Milmo / Hamish Waller Tim Redfern / Sunila de Silva – Broking |
|
|
Yellow Jersey PR |
Tel: +44 (0) 20 3004 9512 |
|
Charles Goodwin / Annabelle Wills / Bessie Elliot
|
|
About Reach announcements
Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only/non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.
About Smarttech247
Smarttech247 is a multi-award winning automated MDR (Managed Detection & Response) company. Its platform is trusted by international organisations and provides threat intelligence with managed detection and response to provide actionable insights, 24/7 threat detection, investigation and response.
The Group's services are geared towards proactive prevention, and it achieves this by utilising the latest technologies, along with an experienced incident response team.
Smarttech247's offices are located in Ireland, United Kingdom, Romania, Poland and the USA. The Company was admitted to trading on the London Stock Exchange on 15 December 2022.
For further information please visitwww.smarttech247.com
*Gartner disclaimers
Market Guide for Managed Detection and Response, 24 June 2024, Pete Shoard, Andrew Davies, Mitchell Schneider, Angel Berrios, Craig Lawson.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the
U.S. and internationally and is used herein with permission. All rights reserved.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRAGPUAGPUPAGBU
CloseOxford BioDynamics PLC – CRC Test Accurately Detects Cancer and Polyps
RNS Number : 9223V Oxford BioDynamics PLC 05 February 2025 Oxford BioDynamics plc ("Oxford BioDynamics" or the "Company") Oxford BioDynamics' EpiSwitch® CRC Blood Test Accurately Detects both Cancer and Polyps · Results of multi-institutional clinical study published in peer reviewed journal 'Cancers' confirms efficacy of Oxford BioDynamics'……
RNS Number : 9223V
Oxford BioDynamics PLC
05 February 2025
Oxford BioDynamics plc
("Oxford BioDynamics" or the "Company")
Oxford BioDynamics' EpiSwitch® CRC Blood Test Accurately
Detects both Cancer and Polyps
· Results of multi-institutional clinical study published in peer reviewed journal 'Cancers' confirms efficacy of Oxford BioDynamics' EpiSwitch® blood-based Colorectal No-Stool Test (NST)
· High accuracy of detection reported at 81% for early cancer stages and 82% for non-cancerous polyps
· Discussions are underway with potential partners to bring this potentially evolutionary test to clinical practice
Oxford, UK – 5 February 2025– Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, announces the publication of compelling results involving OBD's technology in a multi-centre study using blood to detect colorectal cancer (CRC), including early stage, and non-cancerous polyps with high accuracy1.
The peer-reviewed work, published in the high-impact journal 'Cancers', was a collaboration between OBD, Norwich Medical School (University of East Anglia), University Hospitals NHS Trust, Hospital Sultana Bahiyah, Island Hospital Penang, Hospital Pulau Pinang, Hospital Sultanah Aminah, and Mount Miriam Cancer Hospital (Malaysia) under the direction of leading UK and Malaysian colorectal cancer experts.
Usingbloodsamples collected from 325 patients, the whole genome DNA screening for 3D EpiSwitch biomarkers in blood has identified and validated two eight-marker signatures (EpiSwitch® NST) that allow diagnosis of CRC andprecancerous polyps, respectively. Independent validation cohort testing demonstrated an exceptionally highaccuracy of detection – 81% for early cancer stages and 82% for non-cancerous polyps.Linking the top diagnostic biomarkers to nearby genes, OBD used the EpiSwitch KnowledgeBase platform to map pathways that help understand the processes contributing to the pathology of polyp and CRC progression.
Principle clinical lead Prof. Dmitry Pchejetski, Ph.D., Professorial Research Fellow and Head of the Tumour Microenvironment and Chemotherapy group at Norwich Medical School,said:
"I am excited by these findings. This test has the potential ability to detect early cancers and precancerous polyps with greater accuracy."
Dr Alexandre Akoulitchev, OBD's Chief Scientific Officeradded:
"Reliable and non-invasive detection of early stages of colorectal cancer, as well as the polyps, has been the focus of strenuous efforts by a number of big biomarker companies deploying common biomarker modalities. To date the results in terms of sensitivity of detection for polyps and positive predictive value for cancer have been disappointing. Our own approach and these reported results demonstrate the consistent accuracy of EpiSwitch technology for the most challenging patient stratifications and will allow us to progress our ongoing commercial discussions with third parties."
The peer-reviewed manuscript, titled "A New Blood-Based Epigenetic Diagnostic Biomarker Test (EpiSwitch® NST) with High Sensitivity and Positive Predictive Value for Colorectal Cancer and Precancerous Polyps" is available online in Cancers1 (www.mdpi.com/2072-6694/17/3/521).
Colorectal cancer
Globally, CRC is the third most common cancer type, accounting for 10% of all cancer cases. There were 1.9 million new cases and 930,000 deaths from the disease in 2020. More than 80% of CRC arises from adenomatous polyps and outgrowths. Around 75-95% of CRC cases occur in people with little or no genetic risk. Screening modalities such as colonoscopy, faecal immunochemical tests (FIT), FIT-DNA and cell-free DNA from CRC tumours in blood are current primary screening tests for early detection and prevention. Unfortunately, the non-invasive methods lack sensitivity to polyps and early CRC.
OBD's EpiSwitch pipeline development has delivered a blood-based Colorectal No-Stool Test (NST) which shows significant potential as an accurate and rapid cancer screening diagnostic for early stages of cancer (sensitivity 84% and specificity 79%) and non-cancerous polyps (sensitivity 79% and specificity 83%). This accurate, rapid, minimally invasive, and cost-effective NST test was built using OBD's EpiSwitch® 3D genomics platform and methodology. For each patient, NST captures a personal, systemic fingerprint of specific regulatory network changes associated with early stages of colorectal cancer and/or non-cancerous polyps.
References
1"A New Blood-Based Epigenetic Diagnostic Biomarker Test (EpiSwitch® NST) with High Sensitivity and Positive Predictive Value for Colorectal Cancer and Precancerous Polyps"Ewan Hunter 1, Heba Alshaker 2, Cicely Weston 1, Mutaz Issa 1, Shekinah Bautista 1, Abel Gebregzabhar 1, Anya Virdi 1, Ann Dring 1, Ryan Powell 1, Jayne Green 1, Roshan Lal 3, Vamsi Velchuru 3, Kamal Aryal 3, Muhammad Radzi Bin Abu Hassan 4, Goh Tiong Meng 5, Janisha Suriakant Patel 6, Shameera Pharveen Mohamed Gani 6, Chun Ren Lim 6, Thomas Guiel 7, Alexandre Akoulitchev and Dmitri PchejetskiCancers2025, 17, 521. (https://www.mdpi.com/2072-6694/17/3/521)
-Ends-
For more information:
|
Oxford BioDynamics PLC |
+44 (0)1865 518910 |
|
Shore Capital – Nominated Adviser and Joint Broker |
+44 (0)20 7408 4090 |
|
OAK Securities –JointBroker Jerry Keen / Henry Clarke /Damion Carruel |
+44 (0)203 973 3678 |
|
WG Partners – Joint Broker David Wilson / Claes Spång /Satheesh Nadarajah / Erland Sternby |
+44 (0)20 3705 9330 |
|
Vigo Consulting Media / Analyst enquiries for OBD |
+44 (0)20 7390 0230 |
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.
Currently OBD has two commercially available products: the EpiSwitch® PSE (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.
The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.
OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.
The Group's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.
OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, www.oxfordbiodynamics.com, X (@OxBioDynamics) or LinkedIn.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRASSIEFLEISEDE
ClosePowerhouse Energy Group PLC – Proposed collaboration agreement with Avioxx
RNS Number : 8387T Powerhouse Energy Group PLC 20 January 2025 20 January 2025 Powerhouse Energy Group Plc ("Powerhouse", "PHE" or the "Company") Proposed collaboration agreement with Avioxx for the production of SAF Powerhouse (AIM:PHE), a company pioneering integrated technology that converts non-recyclable waste into low……
RNS Number : 8387T
Powerhouse Energy Group PLC
20 January 2025
20 January 2025
Powerhouse Energy Group Plc
("Powerhouse", "PHE" or the "Company")
Proposed collaboration agreement with Avioxx for the production of SAF
Powerhouse (AIM:PHE), a company pioneering integrated technology that converts non-recyclable waste into low carbon energy together with a revenue generating engineering consulting division (Engsolve), is pleased to announce that the Company has agreed to collaborate with Avioxx Ltd (www.avioxx.com)to integrate PHE's technology for its pilot scale facility to produce 200 tonnes per annum of Sustainable Aviation Fuel ("SAF"). Avioxx, based in London and Cheshire, has developed a patented process to produce SAF from non-recyclable wastes.
Under the proposed collaboration, PHE will work with Avioxx on its pilot scale facility, Project Eden, which is expected to produce 200 tonnes per annum of SAF. The companies are currently investigating the potential of PHE providing two 2.5 tonne per day gasification trains to supply the raw syngas to feed the facility. The 2.5 tonne per day units are based upon the Powerhouse's Feedstock Testing Unit at the Company's Technical Centre in Bridgend. These units will be sold to Avioxx, with a potential service agreement going forward between PHE and Avioxx. The integration of the two companies' patented technologies is illustrated in the 3D rendering shown in the figure below.
PHE sees this as an important route to a lower carbon future and the Company's patented DMG (Distributed Modular Generation) is ideal for the smaller scale facilities and will allow its viability as a supplier of Syngas to large scale SAF facilities to be assessed.
Project Eden is still in the development phase and more information about the project and Avioxx can be found athttps://www.avioxx.co.uk/project-eden-200-TPA-modular-plant.html
Details of the Powerhouse Energy Group DMG can be found atwww.phegroup.com
Paul Emmitt, Chief Executive Officer of Powerhouse, commented:
"We are delighted to be collaborating with Avioxx. This is a highly significant development for the Company as it further shows the potential of our technology and its adaptability to be able to service a wide number of industries. SAF has huge potential for us and is a sector that undoubtedly can benefit from using our technology to provide cleaner fuels for the aviation industry.
"We look forward to working with the Avioxx team in progressing Project Eden and providing further updates in due course."
Chris Hancock, Chief Executive Officer of Avioxx, commented:
"Effectively harnessing the valuable molecules from waste is key to achieving a genuine circular economy and delivering economical, sustainable fuel for the aviation sector. We hope the Powerhouse technology will be the first, and most important stage of the process to transform waste to highly valuable fuel. Integration of electrochemistry allows us to dramatically improve the production efficiency of the Jet A1 kerosine. It's great to be working with Paul and the team."
For more information, contact:
Powerhouse Energy Group Plc
Paul Emmitt, CEO +44 (0) 203 368 6399
Strand Hanson Limited(Nominated & Financial Adviser)
Ritchie Balmer / James Harris / Rob Patrick +44 (0) 207 409 3494
SP Angel Corporate Finance LLP(Broker)
Stuart Gledhill / Adam Cowl +44 (0) 20 3470 0470
Tavistock(Financial PR)
Simon Hudson / Nick Elwes / Saskia Sizen +44 (0) 207 920 3150
About Powerhouse Energy Group Plc
Powerhouse has developed a process technology which can utilise waste plastic, end-of-life-tyres, and other waste streams to convert them efficiently and economically into syngas from which valuable products such as chemical precursors, hydrogen, electricity, heat and other industrial products may be derived. PHE's process produces low levels of safe residues and requires a small operating footprint, making it suitable for deployment at enterprise and community level.
PHE also incorporates Engsolve Ltd, which is a revenue generating business offering Engineering Services across all sectors, with speciality services in the development of new technologies and clean energy.
For more information, seewww.phegroup.com
About Avioxx
Avioxx is a UK-based clean energy company pioneering next-generation sustainable aviation fuel production. With a patented solid oxide fuel cell technology, Avioxx is committed to making SAF cost-competitive with traditional jet fuel, reducing aviation emissions, and securing Britain's energy independence.
For more information, see www.avioxx.com
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRAQDLFFEFLZBBV
CloseNeville Registrars welcomes Praetura Growth VCT plc
Neville Registrars are delighted to welcome Praetura Growth VCT plc as the newest addition to its list of client companies. Praetura Growth VCT plc have been providing market-leading investments for advisers and investors since 2011. Their team of experts from across the industry are passionate about finding the best oppportunies in EIS, VCT……
Neville Registrars are delighted to welcome Praetura Growth VCT plc as the newest addition to its list of client companies.
Praetura Growth VCT plc have been providing market-leading investments for advisers and investors since 2011. Their team of experts from across the industry are passionate about finding the best oppportunies in EIS, VCT and BR qualifying companies.
Further information can be found on the Company's website: www.praeturainvestments.co.uk
Close
ValiRx PLC – Contract Award
RNS Number : 7034M ValiRx PLC 19 November 2024 19 November 2024 ValiRx PLC ("ValiRx" or the "Company") Contract Award London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, provides the following contract award update from……
RNS Number : 7034M
ValiRx PLC
19 November 2024
19 November 2024
ValiRx PLC
("ValiRx" or the "Company")
Contract Award
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, provides the following contract award update from its wholly owned subsidiary Inaphaea BioLabs Limited ("Inaphaea").
Inaphaea is delighted to confirm the execution of a further contract for the provision of cell-based assays to UK biotech company, Amply Discovery Limited ("Amply"). The multiphase contract, potentially worth over £100,000 over a 8 month period, will evaluate various formulations of Amply's developmental siRNA targets in Inaphaea's Triple Negative Breast Cancer (TNBC) Patient Derived Cells (PDCs) as stand-alone agents and in combination with standard of care drugs. The deal includes an upfront payment to Inaphaea of approximately £31,000 with an additional approximately £21,000 payment on completion of the first phase after 4 months and £10,500 on completion of the remaining in-vitro phase after a further 6 weeks. Successful candidates have the option to be evaluated in-vivo using selected PDCs through one of Inaphaea's partners.
Andrew Carnegie, Head of Strategic Commercial Development at Inaphaea, commented"It is exciting to have secured this contract, which aligns our services with one of our strategic partners, and defines a good roadmap for future clients."
Mark Eccleston, CEO of ValiRx commented"This is an important contract for Inaphaea as it validates our partnered approach to offering full-service capabilities to our clients."
Dermot Tierney, COO of Amply commented"We are happy to be working with Inaphaea on this critical phase of Amply's development pathway. It was important for us to find a CRO partner who could manage the whole process with agreed milestones."
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company take responsibility for this announcement.
*** ENDS ***
For more information, please contact:
|
ValiRx plc
Dr Mark Eccleston, CEO
|
Tel: +44 (0) 2476 796496
|
|
V Formation (Public Relations)
Lucy Wharton – Senior PR Executive Sue Carr – Director
|
+44 (0) 115 787 0206
lucy@vformation.biz sue@vformation.biz |
|
Cairn Financial Advisers LLP (Nominated Adviser)
Liam Murray/ Ludovico Lazzaretti
|
Tel: +44 (0) 20 7213 0880 |
|
Shard Capital Partners LLP (Sole Broker)
Damon Heath
|
Tel: +44 (0) 20 7186 9000 |
Notes for Editors
About ValiRx
ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.
ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.
Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.
ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.
Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.
ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.
For further information, visit:www.valirx.com
Cautionary statement
Certain statements made in this announcement are forward-looking statements. Such statements are based on current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially from any expected future events or results expressed or implied in these forward-looking statements. Persons receiving this announcement should not place undue reliance on forward-looking statements. Unless otherwise required by applicable law, regulation or accounting standard, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
CNTXVLLFZFLFFBV
CloseKanabo Group PLC – The GP Service Wins Award
RNS Number : 8036M Kanabo Group PLC 19 November 2024 19 November 2024 Kanabo Group Plc The GP Service Wins Award Kanabo Group Plc ("Kanabo" or "the Company"), a leader in medical cannabis and telemedicine innovation, is pleased to announce that its subsidiary, The GP Service, has been named……
RNS Number : 8036M
Kanabo Group PLC
19 November 2024
19 November 2024
Kanabo Group Plc
The GP Service Wins Award
Kanabo Group Plc ("Kanabo" or "the Company"), a leader in medical cannabis and telemedicine innovation, is pleased to announce that its subsidiary, The GP Service, has been named the winner of the Lloyds British Business Excellence Award for Tech Business of the Year. This prestigious recognition highlights The GP Service's leadership in healthcare technology, competing with some of the UK's most forward-thinking companies.
Strategic Growth and Innovation
Since its acquisition by Kanabo in February 2022, The GP Service has strengthened its position in the healthcare market through its robust technology platform and a network of over 6,000 pharmacies across the UK. This infrastructure facilitates secure and seamless electronic prescription delivery, demonstrating its scalability as a patient-focused solution bridging the gap between technology and accessible healthcare.
To align with its strategy of profitability and operational efficiency, The GP Service has restructured its clinical operations by outsourcing services to trusted third-party providers. This move reduces regulatory complexity while sharpening its focus on technology and scalability. This strategic shift enables The GP Service to concentrate on developing innovative solutions that enhance patient access and clinician support.
AI-Driven Expansion
The GP Service continues to refine its proprietary AI-powered Voice and Chat Bot technology, incorporating patient feedback and further testing to optimize its capabilities. Initial beta tests have shown promise. By automating patient consultations, gathering medical data, and supporting clinicians with prescription recommendations, this solution is poised to reduce administrative burdens, improve patient care, and enhance scalability.
Suleman Sacranie, Co-Founder of The GP Service, commented:
"This award is a powerful validation of our mission to make healthcare more accessible, efficient, and patient-focused. Competing against the UK's top technology companies, we're honored to be recognised for our innovation and impact. We look forward to continuing to redefine telemedicine and deliver value to patients and partners."
Ian Mattioli, Chairman of Kanabo Group Plc, added:
"The GP Service's recognition as Tech Company of the Year demonstrates its potential to set new benchmarks in healthcare innovation. While Kanabo supports its growth, The GP Service continues to chart its course as a scalable, technology-driven business delivering value to patients and partners."
Enquiries:
|
Kanabo Group plc Avihu Tamir, Chief Executive Officer Ian Mattioli, Non-Executive Chair of the Board |
|
|
Peterhouse Capital Ltd (Financial Adviser)
|
+44 (0)20 7469 0930 |
About Kanabo Group Plc
Kanabo Group Plc is a pioneering developer of medical cannabis and telemedicine solutions. Through strategic acquisitions and innovative technologies, the company is shaping the future of global healthcare accessibility and outcomes.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRAUKVKRSSUAARA
Close
Neville Registrars Limited, Neville House, Steelpark Road, Halesowen, B62 8HD
Tel: 0121 585 1131
Email: info@nevilleregistrars.co.uk
© Neville Registrars Limited 2026. All Rights Reserved. Registered in England No. 4770411